Pyxis Oncology, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Boston, MA, June 15, 2026 – Pyxis Oncology, Inc. (NASDAQ: PYXS), a clinical-stage oncology company, has released the results of its Annual Meeting of Stockholders held virtually on June 15, 2026. The meeting addressed critical agenda items, with implications for shareholders and the company’s strategic direction in the coming year.

Key Highlights from the Annual Meeting

• Quorum Achieved: At the meeting, a quorum was established as 47,302,035 shares of common stock were represented, either virtually, in person, or by proxy, out of 62,855,464 shares outstanding and eligible to vote as of the record date (April 20, 2026).
• Proposal One: Election of Directors
  • Shareholders voted on the election of directors to the board. The results were as follows:
    • Votes For: 27,341,415
    • Withheld: Data not fully specified in the excerpt
    • Broker Non-Votes: 1,981,857
  • The election of directors is a routine but important item, as board composition influences the company’s strategic direction and governance.
• Proposal Two: Ratification of Independent Registered Public Accounting Firm
  • Shareholders overwhelmingly ratified the appointment of Ernst & Young LLP as the company’s independent auditor for the fiscal year ending December 31, 2026. The vote tallies were:
    • For: 46,203,257
    • Against: Data not fully specified in the excerpt
    • Abstain: Data not fully specified in the excerpt
    • Broker Non-Votes: Data not fully specified in the excerpt
  • The continued engagement of a leading audit firm provides continuity and supports investor confidence in Pyxis Oncology’s financial reporting.

Important Shareholder Information

• Emerging Growth Company Status: Pyxis Oncology continues to qualify as an “Emerging Growth Company” under the SEC’s criteria, allowing for certain reduced reporting requirements and extended transition periods for new or revised financial accounting standards. Notably, the company has elected not to use the extended transition period, indicating its intention to comply with new or revised accounting standards as they become effective for public companies. This may impact the company’s financial reporting and transparency.
• Shareholder Voting Results: No proposals were flagged as controversial or unexpected based on the voting outcomes, and all submitted proposals passed as recommended by the board.
• Company Details:
  • Name: Pyxis Oncology, Inc.
  • Legal Formation: Delaware (DE)
  • Primary Address: 321 Harrison Avenue, Boston, MA 02118
  • Trading Symbol: PYXS
  • Exchange: The Nasdaq Global Select Market
  • Principal Financial and Accounting Officer: Jitendra Wadhane

Potential Price-Sensitive Information

• Audit Firm Ratification: While the ratification of Ernst & Young LLP is routine, it signals stability and adherence to high standards in financial reporting, which can influence investor sentiment.
• Emerging Growth Company Election: The choice to forgo the extended transition period for new accounting standards may suggest management’s confidence in the company’s internal controls and readiness for compliance, potentially viewed favorably by institutional investors.
• No Material Non-Routine Actions: There were no director changes, mergers, acquisitions, or other events announced that would be considered highly price-sensitive or likely to cause significant immediate share price movement.

Conclusion

The 2026 Annual Meeting of Pyxis Oncology, Inc. concluded with the ratification of all management proposals and continued support for the company’s leadership and financial oversight. No material developments outside of standard governance and compliance were reported. Investors should continue to monitor company filings and announcements for updates on clinical progress or strategic initiatives, which are likely to be more impactful for share valuation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research and consult their financial advisors before making investment decisions.

View Pyxis Oncology, Inc. Historical chart here